Status:
RECRUITING
Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Moyamoya Disease
Eligibility:
All Genders
2-60 years
Brief Summary
The purpose of this study is to investigate the long-term outcomes of conservative management in patients with moyamoya disease and their first-degree relatives, and provide potential pathogenesis of ...
Detailed Description
Moyamoya disease (MMD) is a chronic occlusive-stenosis cerebrovascular disease that characterized by the stenosis of internal carotid artery termination and the formation of net-like vessel. It is a m...
Eligibility Criteria
Inclusion
- Patients with age between 2-60 years;
- A clinical diagnosis of moyamoya disease, including unilateral and bilateral disease.
- Patients are medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
- Capable of understanding the purpose and risk of the study and has signed the informed consent. If the participant is not capable of this at the time of enrollment, a legally authorized representative will provide written informed consent in accordance with all regulations.
- Ability to comply with study follow-up.
Exclusion
- Concomitant other diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy.
- Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement.
- Patients are allergic to the contrast agents.
- Patients are treated with direct, indirect, or combined revascularization depending on the presentation.
- Physical or subjective failure to cooperate with the examination or serious comorbid diseases.
- Patients are unable or unlikely to return for follow-up visits.
- Any other reasons that, in the opinion of the investigators, make the participant unsuitable for enrollment.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT05332756
Start Date
May 1 2022
End Date
December 31 2026
Last Update
December 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital Capital Medical University
Beijing, Beijing Municipality, China